ROR1 and mantle cell lymphoma: Studies using drug combinations revealed that inhibitors of several kinases, such as BTK (BCR pathway; ibrutinib, acalabrutinib), FAK (PF431396, VS-4718), and PKC (bryostatin 1, ponatinib) were more effective in killing sensitive MCL cells after shRNA-mediated ROR1 inhibition [124].